RankAlpha logo
Back to Rankings

ABOS

AcumenF
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
A convincing iADRS benefit with acceptable ARIA and supportive secondary endpoints could validate sabirnetug's differentiated approach and support Phase 3 planning.
Posture
Defensive
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-10-26 · BMO.
What can break
Phase 3 design and timing depend on the Phase 2 data and subsequent regulatory discussions.
Momentum
72
Value
41
Sentiment
25
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.40 · Bull $3.50 · Bear $0.40Analysis 2026-10-16; returns require an exact persisted reference.
Earnings
2026-10-26 · BMO
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-16 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-23

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions

Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $7.60
Why
Momentum72 · Δ7d -
Value41 · Δ7d -0.1
Sentiment25 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.

Confirming evidence

  • • Next scheduled catalyst: earnings 2026-10-26 · BMO.
  • • Value remains the lead driver in the composite, 7D delta -0.1.

Contradictions & invalidation

  • • Phase 3 design and timing depend on the Phase 2 data and subsequent regulatory discussions.
  • • The EBD candidates remain preclinical; a targeted mid-2027 IND submission is not an approval milestone.
  • • An inconclusive efficacy result, adverse safety profile or financing on unfavorable terms could overwhelm the pipeline's longer-dated optionality.

Catalyst clock

2026-10-26 · BMO

ALTITUDE-AD Phase 2 topline results

Lead driver: Value · See fundamentals
Momentum
72
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
25
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade F. Momentum 72.3 / Value 40.6 / Sentiment 25.1

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-16. Scenario method

B+
Bull case
20%
Probability
Target price
$3.50
Analysis reference price unavailable
Analysis 2026-10-16 · RankAlpha Sentiment Codex
Most likely
B
Base case
40%
Probability
Target price
$1.40
Analysis reference price unavailable
Analysis 2026-10-16 · RankAlpha Sentiment Codex
B-
Bear case
40%
Probability
Target price
$0.40
Analysis reference price unavailable
Analysis 2026-10-16 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$143.19M
Beta
0.24
Shares Out
72.32M
P/E (TTM) · Derived
-1.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.37
Rev YoY
-100.0%
EPS YoY
-33.0%
Gross Margin
-
Op Margin
-
Net Debt
-$85.55M
Current Ratio
2.47
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data